🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Dry Eye Syndromes

    phase 2 small molecule completed

    1 trial

  2. ADX-2191

    Aldeyra Therapeutics

    Retinitis Pigmentosa

    phase 2 small molecule completed

    1 trial

  3. ADX-629

    Aldeyra Therapeutics

    Chronic Cough

    phase 2 small molecule completed

    1 trial

  4. ADX-629

    Aldeyra Therapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  5. ADX-629

    Aldeyra Therapeutics

    Nephrotic Syndrome

    phase 2 small molecule terminated

    1 trial

  6. ADX-629

    Aldeyra Therapeutics

    Alcohol Hepatitis

    phase 2 small molecule completed

    1 trial

  7. ADX-629

    Aldeyra Therapeutics

    Covid19

    phase 2 small molecule completed

    1 trial

  8. ADX-629

    Aldeyra Therapeutics

    Ethanol Intoxication

    phase 2 small molecule completed

    1 trial

  9. ADX-629

    Aldeyra Therapeutics

    Atopic Asthma

    phase 2 small molecule completed

    1 trial

  10. ADX-629 (Open-label)

    Aldeyra Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  11. ADX10059

    Addex Therapeutics

    Migraine

    phase 2 small molecule terminated

    1 trial

  12. ADX10059

    Addex Therapeutics

    Gastroesophageal Reflux

    phase 2 small molecule completed

    2 trials

  13. ADX48621

    Addex Therapeutics

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  14. AEVI-001

    Avalo Therapeutics

    Attention Deficit Hyperactivity Disorder

    phase 2 small molecule completed

    2 trials

  15. AK104

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. AK112, Cadonilimab, nab-paclitaxel, gemcitabine

    Akeso

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  17. AK117

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  18. ALDESLEUKIN , TIL cells

    Disc Medicine

    Ovarian carcinoma

    phase 2 small molecule active

    1 trial

  19. ALDESLEUKIN , Tumor Intiltrating Lymphocytes (TIL) – VHIO, FLUDARABINE , CYCLOPHOSPHAMIDE

    The George Institute

    Germ Cell Tumors refractory to salvage chemotherapy

    phase 2 small molecule active

    1 trial

  20. ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PDC*lung01, PDC*lung01

    Lacuna Pharma Pty Ltd

    Non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  21. ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

    Lxo Ireland Designated Activity Company

    Sars-CoV2

    phase 2 small molecule completed

    1 trial

  22. ALN-AAT02

    Alnylam Netherlands B.V.

    ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

    phase 2 small molecule terminated

    1 trial

  23. ALN-CIDEB

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 2 small molecule active

    1 trial

  24. ALXN 2040, Placebo matching ALXN2040

    Alexion Europe SAS

    Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources